Cellectis to Report Second Quarter Financial Results on August 6
Clinical-stage biotech firm Cellectis announced it will report its financial results for the second quarter of 2026 on Thursday, August 6, 2026.
New York, NY – July 30, 2026 – Cellectis, a clinical-stage biotechnology company using its gene-editing platform to develop cell and gene therapies, announced it will report its financial results for the second quarter of 2026, ending June 30, 2026. The results will be released after market close on Thursday, August 6, 2026.
The press release detailing the second quarter financial performance will be made available on the Investors section of Cellectis' website. The company will not host a conference call to discuss these results, but its investor relations team will be available for questions via email.
Cellectis focuses on advancing its pipeline of therapies. The company's quarterly financial reports provide key updates on its operational and financial standing. These announcements are closely watched by investors and industry analysts.
The biotechnology firm continues its work in the development of novel therapeutic approaches. The upcoming earnings report will offer insights into the company's progress and strategic direction within the competitive healthcare sector.